Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction
| Autor: | Mark J. Sarnak, Elaine Ku, Wendy McCallum, Deeb N. Salem, Hocine Tighiouart |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Randomization 030232 urology & nephrology Urology Renal function Angiotensin-Converting Enzyme Inhibitors Placebo Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Enalapril medicine Humans 030212 general & internal medicine Mortality Renal Insufficiency Chronic Aged Proportional Hazards Models Heart Failure Creatinine Ejection fraction business.industry Stroke Volume Middle Aged medicine.disease chemistry Nephrology Heart failure Asymptomatic Diseases Multivariate Analysis ACE inhibitor Female business Glomerular Filtration Rate medicine.drug |
| Zdroj: | Am J Kidney Dis |
| ISSN: | 0272-6386 |
| Popis: | RATIONALE & OBJECTIVE: Angiotensin-converting enzyme inhibitors (ACEI) are beneficial in heart failure with reduced ejection fraction (HFrEF). We sought to describe longitudinal trends in estimated glomerular filtration rate (eGFR) in HFrEF and how ACEI therapy influences these changes. STUDY DESIGN: Post-hoc analysis of trial data SETTINGS & PARTICIPANTS: Symptomatic (Treatment Trial, n=2,423) and asymptomatic (Prevention Trial, n=4,094) patients from the Studies Of Left Ventricular Dysfunction (SOLVD) trial. EXPOSURES: Enalapril vs placebo OUTCOMES: Acute and chronic eGFR slope, and 4 kidney endpoints: 1) creatinine increase by ≥0.3 mg/dl; 2) >30% eGFR decline; 3) >40% eGFR decline; 4) incident eGFR of 30%; 2.60 [1.30, 5.21] for eGFR decline >40%; 4.71 [1.78, 12.50] for eGFR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|